Plewman Patrick 4

What Happened
Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics (DGX), exercised stock options to acquire 5,662 shares at $121.81 per share (cost $689,660) and immediately sold those 5,662 shares in the open market at $204.00 per share for proceeds of $1,155,048 on Feb 10, 2026. Separately, on Jan 28, 2026 he received 48 shares valued at $183.51 ($8,809) via a dividend reinvestment plan and elected to report that early.

Key Details

• Transactions:
  • 2026-01-28: Award/acquisition — 48 shares @ $183.51 = $8,809 (reported early; dividend reinvestment) [F1].
  • 2026-02-10: Exercise (M) — 5,662 shares @ $121.81 = $689,660 (acquired).
  • 2026-02-10: Sale (S) — 5,662 shares @ $204.00 = $1,155,048 (disposed).
  • Filing also reports the derivative disposition tied to the exercise (M) as required.
• Footnotes of note:
  • F1: Jan 28 shares from a dividend reinvestment plan; reported early though eligible for deferred Form 5 reporting.
  • F2: The Feb 10 exercise and sale were effected under a prearranged Rule 10b5‑1 sales plan.
  • F3: The original options vested in three equal annual installments beginning on the first anniversary of the grant.
• Shares owned after transaction: Not stated in the provided filing summary.
• Timeliness: Filing dated Feb 12, 2026; transactions on Feb 10 and Jan 28—no late filing indicated in the data provided.

Context
This was effectively a cashless exercise: options were exercised and the resulting shares were sold the same day under a 10b5‑1 plan, a common way executives monetize vested options while following preapproved trading rules. Such sales are routine and reflect execution of a prearranged plan rather than an ad hoc market timing decision.